Article
Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.
Moderator Surabhi Dangi-Garimella asked Daniel Hayes, MD, who has been elected president of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016, what changes practices would have to adopt to implement ASCO’s CancerLinQ.
Currently, ASCO is rolling out CancerLinQ for beta testing in a number of practices, but he admits they don’t really know how it will function until they put it to work.
“I think as it becomes increasingly more successful, other practices will see the advantages of being enrolled,” he said.
How to Choose Between Fixed-Duration vs Continuous BTKi Therapy for CLL